The Global Health Body Raises Warning Over Severe Scarcity of Weight-Loss Medications
Under a tenth of people eligible to benefit from weight-loss injections including Wegovy have access to them, warns the World Health Organization as it publishes its first guidance on the drugs.
Given over a billion individuals worldwide now living with obesity, it is advocating for increased and just access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The new guidance affirms that excess weight is a chronic disease that can be treated with thorough and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are significant barriers to broad availability to the injections that can aid individuals in losing significant body mass, notes the body.
GLP-1 Therapy Supply Crisis
Even in the present most favorable outlook, the production of such drugs could only cover approximately 100 million people – less than 10% of the global need, per the health organization.
The guideline urges nations and manufacturers to expand availability, through approaches including voluntary licensing.
A patent on the active ingredient – the main ingredient of a leading brand – is scheduled to end in several countries in 2026.
The Way Obesity Jabs Operate
GLP-1 drugs imitate a body's own hormone to slow digestion, reduce hunger and increase feelings of fullness so users eat less.
Patients typically begin shedding pounds after several weeks of beginning the once-weekly jabs.
Evidence indicates patients may put most of the weight back on after a year of stopping the treatment, as their usual hunger return.
Being above a healthy weight elevates your likelihood for experiencing diseases, such as diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity concerns people in countries worldwide and was associated with millions of fatalities worldwide in 2024, per the health agency.
